Emzor Pharmaceutical Successfully Repays Debut Series 1 Commercial Paper

Emzor Pharmaceutical has successfully repaid its debut Series 1 Commercial Paper, showcasing its commitment to robust financial management and discipline. The timely repayment has reinforced the company's credit rating and stable outlook.

Emzor has invested 23 million in a facility in Sagamu, Ogun State, to enhance local Active Pharmaceutical Ingredients (API) production, aiming to strengthen Nigeria's drug supply. The company has also implemented advanced ERP software to ensure quality and consumer safety by eliminating substandard and counterfeit medications.

With over 200 registered products distributed across Nigeria and West Africa, Emzor plays a crucial role in enhancing medicine security in the region. The company commends the Nigerian government's policies supporting local pharmaceutical production, including exemptions on import duties and VAT for pharmaceutical raw materials.

Emzor's new API facility is nearing completion, further expanding its healthcare footprint and commitment to building resilient and accessible healthcare across Africa.